1. Home
  2. AHRT vs ACRS Comparison

AHRT vs ACRS Comparison

Compare AHRT & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AH Realty Trust Inc. Common Stock

AHRT

AH Realty Trust Inc. Common Stock

N/A

Current Price

$5.99

Market Cap

471.1M

Sector

Finance

ML Signal

N/A

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

N/A

Current Price

$3.45

Market Cap

529.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AHRT
ACRS
Founded
1979
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
471.1M
529.9M
IPO Year
2013
2015

Fundamental Metrics

Financial Performance
Metric
AHRT
ACRS
Price
$5.99
$3.45
Analyst Decision
Buy
Strong Buy
Analyst Count
4
12
Target Price
$7.50
★ $9.82
AVG Volume (30 Days)
688.0K
★ 2.6M
Earning Date
11-02-2026
11-05-2026
Dividend Yield
★ 9.16%
N/A
EPS Growth
N/A
★ 69.01
EPS
N/A
★ N/A
Revenue
★ $285,201,000.00
$1,683,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$0.96
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.13
$2.46
52 Week High
$7.20
$6.60

Technical Indicators

Market Signals
Indicator
AHRT
ACRS
Relative Strength Index (RSI) 41.50 39.18
Support Level $5.87 $3.24
Resistance Level $6.17 $4.60
Average True Range (ATR) 0.17 0.28
MACD -0.04 -0.02
Stochastic Oscillator 2.60 17.03

Price Performance

Historical Comparison
AHRT
ACRS

About AHRT AH Realty Trust Inc. Common Stock

AH Realty Trust Inc is a real estate investment trust (REIT). It owns, operates, and acquires high-quality properties across the Mid-Atlantic and Southeast, creating lasting value for investors, partners, clients, tenants, and communities. The group focuses on operating and acquiring high-quality, well-positioned assets with growth potential and delivering long-term value for shareholders. Its portfolio includes Harbor Point, Southern Post, The Interlock, and Others.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

Share on Social Networks: